All News
ACR 2019 - Report From Day 2 (Monday)
Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.
The Safety of Methotrexate
Read Article
PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
Read Article
RheumNow Podcast – Better Ways to Treat Gout (11.8.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
T2T Lowers Mortality in Gout
A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.
Read Article
Novel Inhibition of MSU Crystal Inflammation
Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.
Read Article
Patients Prefer Nurse Led Care for their Gout
Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level 6 mg/dl, this goal is seldom achieved ( 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.
Read Article
RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – Women Take Over Rheumatology (10.4.19)
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Read Article
Anakinra Use in Hospitalized Gout Patients
While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.
Read Article
RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Read Article
Higher Rates of Venous Thromboembolism in Gout
A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.
Read Article
RheumNow Podcast – The End of Arthritis (9.13.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Modifiable Risk Factors for Hyperuricemia
Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia.
Read Article
RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)
Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.
Read Article
RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)
Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.
Read Article
NSAIDs Mediate Cardiovascular Risk in OA
NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.
Read Article
RheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog
Links:
Dr. John Cush RheumNow ( View Tweet)
142 pts with ANCA-Associated Vasculitis were studied for lipid levels - Lipid levels increased during remission in newly diagnosed AAV and PR3+ AAV (not MPO or relapsing pts). Lipid levels correlated w/ ESR but not other inammatory markers. https://t.co/9UgUXv6BhI
Links:
Risk of HCQ/CQ Retinal toxicity was 5.5% in 326 SLE pts F/U x 12.8 yrs. None occured in 1st 5 yrs; earliest 8 yrs (max =33 years). Retinal toxicity cases tended to have more renal disease (22% vs 15%) and were slightly less likely to be Caucasian https://t.co/kSFVedbUPY
Dr. John Cush RheumNow ( View Tweet)
FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pulmonary fibrosis (which it is currently approved for). Nintedanib has been studied in PSS ILD. https://t.co/K0ZTyqrfh6
Links:
Dr. John Cush RheumNow ( View Tweet)
